Maria Grazia Roncarolo

List of Publications by Citations

59 papers	11,354 citations	34 h-index	65 g-index
65 ext. papers	12,824 ext. citations	13 avg, IF	5.65 L-index

#	Paper	IF	Citations
59	A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. *Nature*, **1997**, 389, 737-42	50.4	3084
58	Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. *Immunological Reviews*, **2006**, 212, 28-50	11.3	966
57	Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. *Science*, **2002**, 296, 2410-3	33.3	947
56	Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. *Science*, **2013**, 341, 1233158	33.3	837
55	Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. *Science*, **2013**, 341, 1233151	33.3	755
54	Th17 cells express interleukin-10 receptor and are controlled by Foxp3? and Foxp3+ regulatory CD4+ T cells in an interleukin-10-dependent manner. *Immunity*, **2011**, 34, 554-65	32.3	441
53	Regulatory T cells: recommendations to simplify the nomenclature. *Nature Immunology*, **2013**, 14, 307-8	19.1	433
52	Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. *Blood*, **2005**, 105, 1162-9	2.2	401
51	Defective regulatory and effector T cell functions in patients with FOXP3 mutations. *Journal of Clinical Investigation*, **2006**, 116, 1713-22	15.9	383
50	Reprogramming human T cell function and specificity with non-viral genome targeting. *Nature*, **2018**, 559, 405-409	50.4	367
49	Loss of mismatched HLA in leukemia after stem-cell transplantation. *New England Journal of Medicine*, **2009**, 361, 478-88	59.2	337
48	Tr1 cells and the counter-regulation of immunity: natural mechanisms and therapeutic applications. *Current Topics in Microbiology and Immunology*, **2014**, 380, 39-68	3.3	161
47	Human IL2RA null mutation mediates immunodeficiency with lymphoproliferation and autoimmunity. *Clinical Immunology*, **2013**, 146, 248-61	9	141
46	Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency. *Blood*, **2016**, 128, 45-54	2.2	133
45	In Vivo Tracking of Human Hematopoiesis Reveals Patterns of Clonal Dynamics during Early and Steady-State Reconstitution Phases. *Cell Stem Cell*, **2016**, 19, 107-19	18	130
44	The Biology of T Regulatory Type 1 Cells and Their Therapeutic Application in Immune-Mediated Diseases. *Immunity*, **2018**, 49, 1004-1019	32.3	123
43	The cellular and molecular mechanisms of immuno-suppression by human type 1 regulatory T cells. *Frontiers in Immunology*, **2012**, 3, 30	8.4	120

42	In vivo tracking of T cells in humans unveils decade-long survival and activity of genetically modified T memory stem cells. *Science Translational Medicine*, **2015**, 7, 273ra13	17.5	114
41	Hurdles in therapy with regulatory T cells. *Science Translational Medicine*, **2015**, 7, 304ps18	17.5	114
40	Hepatocyte-targeted expression by integrase-defective lentiviral vectors induces antigen-specific tolerance in mice with low genotoxic risk. *Hepatology*, **2011**, 53, 1696-707	11.2	108
39	Killing of myeloid APCs via HLA class I, CD2 and CD226 defines a novel mechanism of suppression by human Tr1 cells. *European Journal of Immunology*, **2011**, 41, 1652-62	6.1	97
38	Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study. *Lancet Haematology,the*, **2019**, 6, e239-e253	14.6	95
37	CD4+ T cells from IPEX patients convert into functional and stable regulatory T cells by FOXP3 gene transfer. *Science Translational Medicine*, **2013**, 5, 215ra174	17.5	89
36	Gene correction for SCID-X1 in long-term hematopoietic stem cells. *Nature Communications*, **2019**, 10, 1634	17.4	77
35	Evidence for long-term efficacy and safety of gene therapy for Wiskott-Aldrich syndrome in preclinical models. *Molecular Therapy*, **2009**, 17, 1073-82	11.7	66
34	Tregopathies: Monogenic diseases resulting in regulatory T-cell deficiency. *Journal of Allergy and Clinical Immunology*, **2018**, 142, 1679-1695	11.5	65
33	Type 1 regulatory T cells are associated with persistent split erythroid/lymphoid chimerism after allogeneic hematopoietic stem cell transplantation for thalassemia. *Haematologica*, **2009**, 94, 1415-26	6.6	53
32	Molecular and functional characterization of allogantigen-specific anergic T cells suitable for cell therapy. *Haematologica*, **2010**, 95, 2134-43	6.6	51
31	Liver gene therapy by lentiviral vectors reverses anti-factor IX pre-existing immunity in haemophilic mice. *EMBO Molecular Medicine*, **2013**, 5, 1684-97	12	49
30	Molecular and functional heterogeneity of IL-10-producing CD4 T cells. *Nature Communications*, **2018**, 9, 5457	17.4	48
29	Insulin B chain 9-23 gene transfer to hepatocytes protects from type 1 diabetes by inducing Ag-specific FoxP3+ Tregs. *Science Translational Medicine*, **2015**, 7, 289ra81	17.5	45
28	Engineered T Regulatory Type 1 Cells for Clinical Application. *Frontiers in Immunology*, **2018**, 9, 233	8.4	44
27	Induction of anergic allergen-specific suppressor T cells using tolerogenic dendritic cells derived from children with allergies to house dust mites. *Journal of Allergy and Clinical Immunology*, **2010**, 125, 727-36	11.5	41
26	Gene Therapy for Adenosine Deaminase Deficiency: A Comprehensive Evaluation of Short- and Medium-Term Safety. *Molecular Therapy*, **2018**, 26, 917-931	11.7	35
25	B-cell reconstitution after lentiviral vector-mediated gene therapy in patients with Wiskott-Aldrich syndrome. *Journal of Allergy and Clinical Immunology*, **2015**, 136, 692-702.e2	11.5	34

24	Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization. *Frontiers in Immunology*, **2017**, 8, 1844	8.4	34
23	Rapamycin combined with anti-CD45RB mAb and IL-10 or with G-CSF induces tolerance in a stringent mouse model of islet transplantation. *PLoS ONE*, **2011**, 6, e28434	3.7	33
22	Gene therapy for primary immunodeficiency. *Human Molecular Genetics*, **2019**, 28, R15-R23	5.6	31
21	Lentiviral Gene Therapy in HSCs Restores Lineage-Specific Foxp3 Expression and Suppresses Autoimmunity in a Mouse Model of IPEX Syndrome. *Cell Stem Cell*, **2019**, 24, 309-317.e7	18	29
20	IL-10-Engineered Human CD4 Tr1 Cells Eliminate Myeloid Leukemia in an HLA Class I-Dependent Mechanism. *Molecular Therapy*, **2017**, 25, 2254-2269	11.7	28
19	B-cell development and functions and therapeutic options in adenosine deaminase-deficient patients. *Journal of Allergy and Clinical Immunology*, **2014**, 133, 799-806.e10	11.5	27
18	Coexpression of CD163 and CD141 identifies human circulating IL-10-producing dendritic cells (DC-10). *Cellular and Molecular Immunology*, **2020**, 17, 95-107	15.4	27
17	Graft Engineering and Adoptive Immunotherapy: New Approaches to Promote Immune Tolerance After Hematopoietic Stem Cell Transplantation. *Frontiers in Immunology*, **2019**, 10, 1342	8.4	23
16	Peanut-specific type 1 regulatory T cells induced in vitro from allergic subjects are functionally impaired. *Journal of Allergy and Clinical Immunology*, **2018**, 141, 202-213.e8	11.5	20
15	Genome editing of donor-derived T-cells to generate allogenic chimeric antigen receptor-modified T cells: Optimizing T cell-depleted haploidentical hematopoietic stem cell transplantation. *Haematologica*, **2021**, 106, 847-858	6.6	18
14	Immune responses in liver-directed lentiviral gene therapy. *Translational Research*, **2013**, 161, 230-40	11	15
13	Role of human forkhead box P3 in early thymic maturation and peripheral T-cell homeostasis. *Journal of Allergy and Clinical Immunology*, **2018**, 142, 1909-1921.e9	11.5	12
12	APVO210: A Bispecific Anti-CD86-IL-10 Fusion Protein (ADAPTIR) to Induce Antigen-Specific T Regulatory Type 1 Cells. *Frontiers in Immunology*, **2018**, 9, 881	8.4	12
11	Development of globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease. *Science Translational Medicine*, **2021**, 13,	17.5	12
10	Engineered type 1 regulatory T cells designed for clinical use kill primary pediatric acute myeloid leukemia cells. *Haematologica*, **2021**, 106, 2588-2597	6.6	4
9	Lentiviral Mediated Gene Therapy for Pyruvate Kinase Deficiency: Interim Results of a Global Phase 1 Study for Adult and Pediatric Patients. *Blood*, **2021**, 138, 563-563	2.2	2
8	Alloantigen-specific type 1 regulatory T cells suppress through CTLA-4 and PD-1 pathways and persist long-term in patients. *Science Translational Medicine*, **2021**, 13, eabf5264	17.5	2
7	The Yin and Yang of Type 1 Regulatory T Cells: From Discovery to Clinical Application. *Frontiers in Immunology*, **2021**, 12, 693105	8.4	2

6	InsB9-23 Gene Transfer to Hepatocyte-Based Combined Therapy Abrogates Recurrence of Type 1 Diabetes After Islet Transplantation. *Diabetes*, **2021**, 70, 171-181	0.9	1
5	Pre-clinical development and molecular characterization of an engineered type 1 regulatory T-cell product suitable for immunotherapy. *Cytotherapy*, **2021**, 23, 1017-1028	4.8	1
4	Co-Expression of FOXP3FL and FOXP3Δ2 Isoforms Is Required for Optimal Treg-Like Cell Phenotypes and Suppressive Function. *Frontiers in Immunology*, **2021**, 12, 752394	8.4	0
3	BHLHE40 Regulates IL-10 and IFN- Production in T Cells but Does Not Interfere With Human Type 1 Regulatory T Cell Differentiation. *Frontiers in Immunology*, **2021**, 12, 683680	8.4	0
2	Engineering Human Invariant Natural Killer T (iNKT) Cells to Overexpress Immunomodulatory Cytokines. *Blood*, **2021**, 138, 3888-3888	2.2	
1	The Women of FOCIS: Promoting Equality and Inclusiveness in a Professional Federation of Clinical Immunology Societies.. *Frontiers in Immunology*, **2022**, 13, 816535	8.4	